US › Healthcare

Eupraxia Pharmaceuticals Inc. Common Stock (EPRX)

US · Healthcare · Biotechnology

$6.52+0.15%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-12.5M

Profit YoY

-84.5%

EPS

$-0.23

EPS estimate

$-0.17

EPS came in at -0.23 against a street estimate of -0.17 — a miss of 37.6%.

Key statistics

Market cap

$418.1M

Forward P/E

0.0

P/B

3.87

Book value

$1.75

EPS (TTM)

$-1.05

52-week high

$9.32

52-week low

$5.04

50-day MA

$6.47

200-day MA

$7.00

Beta

1.50

Analyst view

with an average price target of $16.39.

Shareholding

Insiders

14.22%

Institutions

41.39%

Largest institutional holders

Fund	Stake
Beutel, Goodman & Company Ltd.	5.61%
Affinity Asset Advisors, LLC	2.43%
Vivo Capital, LLC	2.07%
Balyasny Asset Management LLC	2.07%
Scotia Capital Inc	2.05%
Ikarian Capital, LLC	1.86%
Great Point Partners LLC	1.84%
Point72 Asset Management, L.P.	1.48%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Eupraxia Pharmaceuticals Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.